TriClip G4: A game-changer for tricuspid valve regurgitation treatment.
Curr Probl Cardiol
; 49(8): 102687, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38821232
ABSTRACT
Tricuspid valve regurgitation, or TR, is a difficult-to-manage condition. In addition to EVOQUE, percutaneous annuloplasty, and surgical repair, the TriClip G4 system has been added to the interventional therapeutic choices for TR. Recently, the Food and Drug Administration (FDA) approved the use of the TriClip G4 device to treat patients with symptomatic, severe TR who have received optimal medication therapy but are at intermediate or higher risk of surgery. This review attempts to offer a thorough examination of the procedural features, learning curves, results of the device and compares the TriClip G4 system to other interventional therapies for TR. TriClip G4 has shown to have promising results in pivotal clinical trials, be cost-effective, and improve the quality of life of patients. Furthermore, it has its unique advantages against other conventional techniques and devices.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Valva Tricúspide
/
Insuficiência da Valva Tricúspide
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article